Perioperative Interdisciplinary, Intersectoral Process Optimization in Heart Failure

ConditionHeart Failure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorUniversity of Giessen

About this trial

Chronic heart failure affects up to three million people in Germany, with prevalence increasing with age. It is a leading cause of cardiovascular disease-related deaths. Patients with heart failure undergoing non-cardiac surgery face higher risks of complications and death compared to those with coronary artery disease. Despite guidelines recommending comprehensive preoperative evaluation, there is no systematic risk assessment structure in place, leading to inadequate perioperative care. This study aims to evaluate a multidisciplinary approach for high-risk patients aged 65 and above, regardless of prior heart failure diagnosis, to mitigate postoperative complications. The investigators measure the NTpro BNP before surgery and include patients with NTproBNP\> 450 in this study and randomize them either to the standard care group or the intervention group.The hypothesis is that standardized risk screening and multidimensional care (Intervention group) can reduce complications in these patients undergoing non-cardiac surgery.

Eligibility criteria

Qualifiers

Age ≥ 65 years

Elective non-cardiac surgical operation with intermediate or high operative risk under general anesthesia or combined anesthesia (general and regional anesthesia) as per Figure 1

ASA (American Society of Anesthesiologists) grade ≥ II

Qualification for randomization: NT-proBNP ≥ 450pg/ml during routine preoperative evaluation and anesthesia consultation.

Disqualifiers

Age < 65 years

Cardiac surgery and cardiology interventional procedures

Transplantation surgery (e.g., kidney, liver, lung transplantation)

Kidney surgery (e.g., nephrectomy, partial nephrectomy)

Trial design

Treatments tested in this trial

  • Interdisciplinary decision-making for perioperative care

Treatment groups

1,057 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Giessen

Lead sponsor

Deutsche Luft und Raumfahrt

Collaborator